

Date: 21 May 2021

**Re: Freedom of Information Request**  
**Ref: 119-2021**

Thank you for your email dated the 26<sup>th</sup> April 2021, requesting information in relation to patient treatment figures.

The information that you require is as follows:

**Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:**

**1. How many patients were treated (for any condition) in the past 6 months with:**

- **Abiraterone = 253**
- **Apalutamide = Exempt under S.40**
- **Cabazitaxel = 27**
- **Darolutamide = 6**
- **Docetaxel = 68**
- **Enzalutamide = 315**
- **Ruxolitinib = 17**

**2. Please provide the total number of patients treated in the last 6 months for:**

- **Myelofibrosis (ICD10 code D47.4) =12**
- **Myelofibrosis (ICD10 code D47.4) – patients over the age 65 = 6**
- **Prostate cancer = 1017**

- **Metastatic prostate cancer = 562 (patient received 2<sup>nd</sup> or more course of SACT)**

**3. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?**

**N/A – As a tertiary specialist cancer treatment centre, we do not perform diagnostics.**

- **Of these patients, how many were treated in the past 6 months with Hydroxyurea?**
- **Of these patients, how many have received no active treatment in the past 6 months?**

**4. How many metastatic prostate cancer patients were treated in the past 6 months with:**

**(For patient received 2<sup>nd</sup> or more course of SACT)**

- **Abiraterone = 212**
- **Apalutamide = Exempt under S.40**
- **Cabazitaxel = 27**
- **Darolutamide = 6**
- **Docetaxel = Exempt under S.40**
- **Enzalutamide = 179**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**